Tag Archives: Antibody-drug conjugates

October, 2017

  • 26 October

    New Study: ‘Double Decker’ Antibody Technology Fights Cancer

    JUPITER, Fla., Oct. 25, 2017 /PRNewswire-USNewswire/ — Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), using a versatile “double decker” technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy. The new …

May, 2017

March, 2017

October, 2015

  • 28 October

    Igenica Partners with MedImmune to Research Anti-SAIL ADCs

    BURLINGAME, Calif.–(BUSINESS WIRE)–Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative antibody-based therapies for the treatment of cancer, announced today that it has entered into an oncology research agreement with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN). Igenica and MedImmune will …

April, 2015